Analysis of Differential Expression of microRNAs and Their Target Genes in Prostate Cancer: A Bioinformatics Study on Microarray Gene Expression Data.
Analysis of Differential Expression of microRNAs and Their Target Genes in Prostate Cancer: A Bioinformatics Study on Microarray Gene Expression Data.
复制标题
DOI：
10.22088/ijmcm.bums.8.2.103
复制
发表时间：
2019-01-01
影响因子：
--
通讯作者：
Mahdian, Reza
中科院分区：
文献类型：
--
作者：
Khorasani, Maryam;Shahbazi, Shirin;Mahdian, Reza
前列腺癌（PCa）作为男性第二大常见癌症的早期诊断与精确和特异性结果无关。因此，需要具有高特异性和灵敏度的替代方法来准确和及时地检测PCa。microRNA通过靶向多个基因来调节参与癌症的分子途径。在不同的癌症类型包括PCa中已经报道了microRNA的异常表达。在这项生物信息学研究中，我们研究了microRNA及其靶基因在四个PCa基因表达综合数据库（GEO）中的差异表达谱。使用生物信息学工具研究PCa诊断生物标志物候选物，以分析基因表达数据、microRNA靶标预测、途径和GO注释以及ROC曲线。这项研究的结果揭示了14种microRNA和40种相关靶基因表达的显著变化，它最终组成了四个组合面板，（miR- 375+96+663/ miR- 133b+143- 3p + 205/ C2ORF72 + ENTPD 5 + GLYAT 11/LAMB 3 + NTNG 2 +TSLP）作为能够区分PCa肿瘤样品和正常前列腺组织样品的候选生物标志物。这些生物标志物可被建议用于PCa患者的更准确的早期诊断沿着当前的诊断测试。
Early diagnosis of prostate cancer (PCa) as the second most common cancer in men is not associated with precise and specific results. Thus, alternate methods with high specificity and sensitivity are needed for accurate and timely detection of PCa. MicroRNAs regulate the molecular pathways involved in cancer by targeting multiple genes. The aberrant expression of the microRNAs has been reported in different cancer types including PCa. In this bioinformatics study, we studied differential expression profiles of microRNAs and their target genes in four PCa gene expression omnibus (GEO) databases. PCa diagnostic biomarker candidates were investigated using bioinformatics tools for analysis of gene expression data, microRNA target prediction, pathway and GO annotation, as well as ROC curves. The results of this study revealed significant changes in the expression of 14 microRNAs and 40 relevant target genes, which ultimately composed four combination panels (miR- 375+96+663/ miR- 133b+143- 3p + 205/ C2ORF72 + ENTPD5 + GLYAT11/LAMB3 + NTNG2+TSLP) as candidate biomarkers capable to distinguish between PCa tumor samples and normal prostate tissue samples. These biomarkers may be suggested for a more accurate early diagnosis of PCa patients along with current diagnostic tests.